Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach

This publication has 41 references indexed in Scilit:

• Molecular modeling studies to characterize N -phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations
  Molecular BioSystems, 2016
• CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
  Clinical Cancer Research, 2015
• The history and future of targeting cyclin-dependent kinases in cancer therapy
  Nature Reviews Drug Discovery, 2015
• 3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis
  Acta Pharmacologica Sinica, 2013
• CDK4: A Key Player in the Cell Cycle, Development, and Cancer
  Genes & Cancer, 2012
• A Medicinal Chemist’s Guide to Molecular Interactions
  Journal of Medicinal Chemistry, 2010
• Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses
  Bioorganic & Medicinal Chemistry, 2008
• 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: An insight into the criteria for selectivity
  European Journal of Medicinal Chemistry, 2007
• Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin
  Organic & Biomolecular Chemistry, 2006
• The blood–brain barrier: an overview
  Neurobiology of Disease, 2004